Glioblastoma Multiforme (GBM) is one of the deadliest forms of brain cancer -- and CNS Pharma wants to do something about it. They’re in the midst of developing Berubicin, a breakthrough drug whose clinical trials have yielded promising results. Berubicin was created at MD Anderson Cancer Center, and it’s the first of its class of drugs to cross the blood brain barrier and reach cancer cells in brain tumor patients. It’s also been granted Orphan Drug status by the US FDA, and CNS expects to start its Phase 2(a) clinical trial soon. CNS has also entered into a collaboration agreement with Reata Pharmaceuticals and plans to list on the NASDAQ in 2018.